SEARCH:   Advanced

Blood, 1 January 2007, Vol. 109, No. 1, pp. 290-297. Prepublished online as a Blood First Edition Paper on September 7, 2006; DOI 10.1182/blood-2006-03-007567. This Article Full Text (PDF) All Versions of this Article: blood-2006-03-007567v1 109/1/290    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nuckel, H. Articles by Siffert, W. Search for Related Content PubMed PubMed Citation Articles by Nuckel, H. Articles by Siffert, W. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 6, 2006 Accepted August 16, 2006 Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia Holger Nuckel*, Ulrich H Frey, Maja Bau, Ludger Sellmann, Jens Stanelle, Jan Durig, Karl-Heinz Jockel, Ulrich Duhrsen, and Winfried Siffert Dept. of Hematology, Institute of Pharmaco. Medical Faculty, University of Duisburg-Essen, Germany Institute of Pharmacogenetics, Medical Faculty, University of Duisburg-Essen, Germany Institute of Pharmacogenetics Dept. of Hematology, Institute of Cell Bio, Medical Faculty, University of Duisburg-Essen, Germany Institute of Cell Biology (Tumor research), University of Duisburg-Essen, Germany Department of Hematology, Medical Faculty, University of Duisburg-Essen, Germany Institute for Medical Informatics, Biometry and Epidemiology Institute for Medical Informatics, Medical Faculty, University of Duisburg-Essen, Germany * Corresponding author; email: holger.nueckel{at}uni-essen.de. Bcl-2 plays a key role in the regulation of apoptosis. We investigated the role of a novel regulatory single nucleotide polymorphism (-938C>A) in the inhibitory P2 BCL2 promoter in B-CLL. The -938C-allele displayed significantly increased BCL2 promoter activity and binding of nuclear proteins compared to the A-allele. Concomitantly, Bcl-2 protein expression in B-cells from CLL patients carrying the -938 AA genotype was significantly increased compared to CC genotypes. Genotype distribution between 123 CLL patients (42 AA, 55 AC, 26 CC) and 120 genotyped healthy controls (36 AA, 63 AC, 21 CC) was not significantly different suggesting that genotypes of this polymorphism do not increase the susceptibility for B-CLL. However, median time from first diagnosis to initiation of chemotherapy and median overall survival were significantly shorter in patients with -938AA genotype (38 and 199 months, respectively) compared to AC/CC genotypes (120 and 321 months, respectively; p=0.0077 and p=0.003, respectively). Multivariable Cox regression identified the BCL2 -938AA genotype as an independent prognostic factor for the time to first treatment (hazard ratio, HR, 1.9; p=0.034) together with disease stage at diagnosis (HR 2.5; p=0.004) and ZAP-70 status (HR 3.0; p=0.001). The BCL2 -938AA genotype is associated with increased Bcl-2 expression and a novel unfavorable genetic marker in patients with B-CLL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Prognostic assessment of BCL2-938C>A polymorphism in chronic lymphocytic leukemia Davide Rossi, Silvia Rasi, Daniela Capello, and Gianluca Gaidano Blood 2008 111: 466-468. [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020